Red Book Online Quick Search Advanced Search

This Article Images Only Full Version Services E-mail this link to a friend Related text in Red Book Add to My File Cabinet Download to citation manager Articles in Pediatrics Section 1 Section 2 Section 3 Section 4 Section 5 Appendices

The first 300 words of the full text of this section appear below.

Section 3. Summaries of Infectious Diseases

Measles

Clinical Manifestations
Etiology
Epidemiology
Diagnostic Tests
Treatment
Isolation of the Hospitalized Patient
Control Measures

Top Next

CLINICAL MANIFESTATIONS: Measles is an acute disease characterized by fever, cough, coryza, conjunctivitis, an erythematous maculopapular rash, and a pathognomonic enanthema (Koplik spots). Complications including otitis media, bronchopneumonia, laryngotracheobronchitis (croup), and diarrhea occur commonly in young children. Acute encephalitis, which often results in permanent brain damage, occurs in approximately 1 of every 1000 cases. Death, predominantly resulting from respiratory and neurologic complications, occurs in 1 to 3 of every 1000 cases reported in the United States. Case fatality rates are increased in children younger than 5 years of age and immunocompromised children, including children with leukemia, human immunodeficiency virus (HIV) infection, and severe malnutrition. Sometimes the characteristic rash does not develop in immunocompromised patients.

Subacute sclerosing panencephalitis (SSPE) is a rare degenerative central nervous system disease characterized by behavioral and intellectual deterioration and seizures. Widespread measles immunization has led to the virtual disappearance of SSPE in the United States.

Top Previous Next

ETIOLOGY: Measles virus is an RNA virus with 1 serotype, classified as a member of the genus Morbillivirus in the Paramyxoviridae family.

Top Previous Next

EPIDEMIOLOGY: The only natural hosts of measles virus are humans. Measles is transmitted by direct contact with infectious droplets or, less commonly, by airborne spread. In temperate areas, the peak incidence of infection usually occurs during late winter and spring. In the prevaccine era, most cases of measles in the United States occurred in preschool and young school-aged children, and few people remained susceptible by 20 years of age. The childhood and adolescent immunization program in the United States has resulted in a greater than 99% decrease in the reported incidence of measles since measles vaccine was first licensed in 1963.

From 1989 to 1991, the incidence of . . . [Go to Full Text]

Related text in Red Book:

Active Immunization of People Who Recently Received Immune Globulin

Red Book 2006: 36-37. [Extract] [Full Version]  

Vaccine Safety and Contraindications

Red Book 2006: 39-41. [Extract] [Full Version]  

Vaccine Handling and Storage

Red Book 2006: 12-18. [Extract] [Full Version]  

Minimum Ages and Minimum Intervals Between Vaccine Doses

Red Book 2006: 25-33. [Extract] [Full Version]  

Simultaneous Administration of Multiple Vaccines

Red Book 2006: 34. [Extract] [Full Version]  

Immune Globulin (Intramuscular)

Red Book 2006: 55-57. [Extract] [Full Version]  

Health Care Personnel

Red Book 2006: 94-96. [Extract] [Full Version]  

International Travel

Red Book 2006: 98-103. [Extract] [Full Version]  

Immunocompromised Children

Red Book 2006: 71-85. [Extract] [Full Version]  

Children With a Personal or Family History of Seizures

Red Book 2006: 85. [Extract] [Full Version]  

Active Immunization After Exposure to Disease

Red Book 2006: 86-87. [Extract] [Full Version]  

Children in Residential Institutions

Red Book 2006: 90-92. [Extract] [Full Version]  

Infectious Diseases—Epidemiology and Control

Red Book 2006: 135-142. [Extract] [Full Version]  

Rubella

Red Book 2006: 574-579. [Extract] [Full Version]  

Tuberculosis

Red Book 2006: 678-698. [Extract] [Full Version]  

Varicella-Zoster Infections

Red Book 2006: 711-725. [Extract] [Full Version]  

Human Immunodeficiency Virus Infection

Red Book 2006: 378-401. [Extract] [Full Version]  

Kawasaki Disease (Mucocutaneous Lymph Node Syndrome)

Red Book 2006: 412-415. [Extract] [Full Version]  

Mumps

Red Book 2006: 464-468. [Extract] [Full Version]  

Guide to Contraindications and Precautions to Immunizations, 2006

Red Book 2006: 847-851. [Extract] [Full Version]  

2006 Red Book Erratum, P. 682

Red Book 2006: E8. [Extract] [Full Version]  

This topic has been referenced by these articles:

• Chalmers, I. (2002). Why We Need to Know Whether Prophylactic Antibiotics Can Reduce Measles-Related Morbidity. Pediatrics 109: 312-315 [Abstract] [Full Version]  
• Abbott;, M., Gerber, M. A., Halsey, N. A., Abramson, J. S. (2001). Varicella Vaccine Question. Pediatrics 107: 612-612 [Full Version]  
• Klein, J. O., Myers, M. G. (2006). Vaccine shortages: why they occur and what needs to be done to strengthen vaccine supply.. Pediatrics 117: 2269-2275 [Full Version]  
• Puliyel, J. M. (2002). The Dummies' Guide to Risk-Benefit Analysis of Vaccines. Pediatrics 110: 193-193 [Full Version]  
• Pelton, S. I. (2004). The Decline in Invasive Pneumococcal Disease. Pediatrics 113: 617-618 [Full Version]  
• Dayan, G. H., Ortega-Sanchez, I. R., LeBaron, C. W., Quinlisk, M. P., and the Iowa Measles Response Team, (2005). The Cost of Containing One Case of Measles: The Economic Impact on the Public Health Infrastructure--Iowa, 2004. Pediatrics 116: e1-e4 [Abstract] [Full Version]  
• Perez, E. E., Bokszczanin, A., McDonald-McGinn, D., Zackai, E. H., Sullivan, K. E. (2003). Safety of Live Viral Vaccines in Patients With Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome). Pediatrics 112: e325-325 [Abstract] [Full Version]  
• Bonilla, F. A. (2004). SAFETY OF LIVE VIRAL VACCINES IN PATIENTS WITH CHROMOSOME 22Q11.2 DELETION SYNDROME (DiGEORGE SYNDROME/VELOCARDIOFACIAL SYNDROME). Pediatrics 114: 550-550 [Full Version]  
• WHEATLEY, G. M., ARENA, J. M., KOTTE, R. H., HOYER, B. J. (1952). Round Table Discussion: PREVENTION OF ACCIDENTS IN CHILDHOOD. Pediatrics 9: 237-242 [Abstract]  
• Melvin, A. J., Mohan, K. M. (2003). Response to Immunization With Measles, Tetanus, and Haemophilus influenzae Type b Vaccines in Children Who Have Human Immunodeficiency Virus Type 1 Infection and Are Treated With Highly Active Antiretroviral Therapy. Pediatrics 111: e641-644 [Abstract] [Full Version]  
• (2006). Reisinger KS, Hoffman Brown ML, Xu J, et al. A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax. PEDIATRICS 2006;117:265-272.. Pediatrics 117: 2338-2338 [Full Version]  
• Pool, V., Braun, M. M., Kelso, J. M., Mootrey, G., Chen, R. T., Yunginger, J. W., Jacobson, R. M., Gargiullo, P. M. (2002). Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After Measles-Mumps-Rubella Vaccine in the United States. Pediatrics 110: e71-71 [Abstract] [Full Version]  
• Fombonne, E., Zakarian, R., Bennett, A., Meng, L., McLean-Heywood, D. (2006). Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations. Pediatrics 118: e139-e150 [Abstract] [Full Version]  
• Bekker, V., Scherpbier, H., Pajkrt, D., Jurriaans, S., Zaaijer, H., Kuijpers, T. W. (2006). Persistent Humoral Immune Defect in Highly Active Antiretroviral Therapy-Treated Children With HIV-1 Infection: Loss of Specific Antibodies Against Attenuated Vaccine Strains and Natural Viral Infection. Pediatrics 118: e315-e322 [Abstract] [Full Version]  
• Fombonne, E., Chakrabarti, S. (2001). No Evidence for A New Variant of Measles-Mumps-Rubella-Induced Autism. Pediatrics 108: e58-58 [Abstract] [Full Version]  
• Maloney, J., Sicherer, S. H. (2005). No Epidemiological Evidence for Infant Vaccination to Cause Allergic Disease. Pediatrics 116: 542-542 [Full Version]  
• Taha, T. E., Graham, S. M., Kumwenda, N. I., Broadhead, R. L., Hoover, D. R., Markakis, D., van der Hoeven, L., Liomba, G. N., Chiphangwi, J. D., Miotti, P. G. (2000). Morbidity Among Human Immunodeficiency Virus-1-Infected and -Uninfected African Children. Pediatrics 106: 77e-77 [Abstract] [Full Version]  
• Halsey, N. A., Hyman, S. L., the Conference Writing Panel, (2001). Measles-Mumps-Rubella Vaccine and Autistic Spectrum Disorder: Report From the New Challenges in Childhood Immunizations Conference Convened in Oak Brook, Illinois, June 12-13, 2000. Pediatrics 107: 84e-84 [Abstract] [Full Version]  
• Meissner, H. C., Strebel, P. M., Orenstein, W. A. (2004). Measles Vaccines and the Potential for Worldwide Eradication of Measles. Pediatrics 114: 1065-1069 [Abstract] [Full Version]  
• Leitch, R., Halsey, N., Hyman, S. L. (2002). MMR--Separate Administration--Has It Been Done?. Pediatrics 109: 172-172 [Full Version]  
• Piedra, P. A., Gaglani, M. J., Riggs, M., Herschler, G., Fewlass, C., Watts, M., Kozinetz, C., Hessel, C., Glezen, W. P. (2005). Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label Trial. Pediatrics 116: e397-e407 [Abstract] [Full Version]  
• Bellamy, C. (2004). International Pediatric Congress. Pediatrics 114: 1088-1089 [Full Version]  
• Yogev, R. (2006). Influenza Vaccine for School-Aged Children: In Reply. Pediatrics 118: 841-842 [Full Version]  
• Miller, L. C., Comfort, K., Kelly, N. (2001). Immunization Status of Internationally Adopted Children. Pediatrics 108: 1050-1051 [Full Version]  
• Rosenthal, J., Rodewald, L., McCauley, M., Berman, S., Irigoyen, M., Sawyer, M., Yusuf, H., Davis, R., Kalton, G. (2004). Immunization Coverage Levels Among 19- to 35-Month-Old Children in 4 Diverse, Medically Underserved Areas of the United States. Pediatrics 113: e296-e302 [Abstract] [Full Version]  
• Posfay-Barbe, K. M., Heininger, U., Aebi, C., Desgrandchamps, D., Vaudaux, B., Siegrist, C.-A. (2005). How Do Physicians Immunize Their Own Children? Differences Among Pediatricians and Nonpediatricians. Pediatrics 116: e623-e633 [Abstract] [Full Version]  
• Stiehm, E. R. (2006). Disease Versus Disease: How One Disease May Ameliorate Another. Pediatrics 117: 184-191 [Abstract] [Full Version]  
• Virtanen, M., Peltola, H., Paunio, M., Heinonen, O. P. (2000). Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination. Pediatrics 106: 62e-62 [Abstract] [Full Version]  
• Nilsson, A., De Milito, A., Engstrom, P., Nordin, M., Narita, M., Grillner, L., Chiodi, F., Bjork, O. (2002). Current Chemotherapy Protocols for Childhood Acute Lymphoblastic Leukemia Induce Loss of Humoral Immunity to Viral Vaccination Antigens. Pediatrics 109: e91-91 [Abstract] [Full Version]  
• Zerr, D. M., Heath, J., Riggert, D., Marcuse, E. K., Zimmerman, L., Reef, S. E. (2001). Congenital Rubella Infection Control Problem. Pediatrics 108: 1389-1390 [Full Version]  
• Brosco, J. P. (2005). Commentary: Successes and Missed Opportunities. Pediatrics 115: 1134-1135 [Full Version]  
• Smith, P. J., Chu, S. Y., Barker, L. E. (2004). Children Who Have Received No Vaccines: Who Are They and Where Do They Live?. Pediatrics 114: 187-195 [Abstract] [Full Version]  
• Kohrt, A. E. (2003). Child and Adolescent Immunizations: New Recommendations, New Standards, New Opportunities. Pediatrics 112: 978-981 [Full Version]  
• Meissner, H. C., Anderson, L. J., Pickering, L. K. (2004). Annual Variation in Respiratory Syncytial Virus Season and Decisions Regarding Immunoprophylaxis With Palivizumab. Pediatrics 114: 1082-1084 [Full Version]  
• Guyer, B., Freedman, M. A., Strobino, D. M., Sondik, E. J. (2000). Annual Summary of Vital Statistics: Trends in the Health of Americans During the 20th Century. Pediatrics 106: 1307-1317 [Abstract] [Full Version]  
• Patja, A., Mäkinen-Kiljunen, S., Davidkin, I., Paunio, M., Peltola, H. (2001). Allergic Reactions to Measles-Mumps-Rubella Vaccination. Pediatrics 107: 27e-27 [Abstract] [Full Version]  
• Freeman, A. F., Jacobsohn, D. A., Shulman, S. T., Bellini, W. J., Jaggi, P., Leon, G. d., Keating, G. F., Kim, F., Pachman, L. M., Kletzel, M., Duerst, R. E. (2004). A New Complication of Stem Cell Transplantation: Measles Inclusion Body Encephalitis. Pediatrics 114: e657-e660 [Abstract] [Full Version]  
• Yeung, L. F., Lurie, P., Dayan, G., Eduardo, E., Britz, P. H., Redd, S. B., Papania, M. J., Seward, J. F. (2005). A Limited Measles Outbreak in a Highly Vaccinated US Boarding School. Pediatrics 116: 1287-1291 [Abstract] [Full Version]  
• Reisinger, K. S., Hoffman Brown, M. L., Xu, J., Sullivan, B. J., Marshall, G. S., Nauert, B., Matson, D. O., Silas, P. E., Protocol 014 Study Group for ProQuad, , Schodel, F., Gress, J. O., Kuter, B. J. (2006). A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax. Pediatrics 117: 265-272 [Abstract] [Full Version]  

Site Requirements | Privacy Policy | Core Values, Vision, and Mission Statement
The recommendations in this online publication do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.
Copyright © 2006 American Academy of Pediatrics